News

Dr. Goy Discusses Ibrutinib With Venetoclax in MCL

Andre Goy, M.D., chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Read full article on onclive.com.